The therapeutic effects of Portulaca oleracea L. in hepatogastric disorders.

Agresión oxidativa Gastroprotective Gastroprotector Hepatoprotective Hepatoprotector Inflamación Inflammation Oxidative stress Portulaca oleracea L.

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 28 10 2017
revised: 20 06 2018
accepted: 27 07 2018
pubmed: 18 10 2018
medline: 13 9 2019
entrez: 18 10 2018
Statut: ppublish

Résumé

This research was conducted to obtain accurate information on the protective effects of Portulaca oleracea L. against hepatogastric diseases. P. oleracea L. (Purslane) has traditionally been used for the treatment of hepatogastric diseases. However, the low number of research studies has shown that P. oleracea L. possesses protective effects against hepatotoxic agents. The safety of P. oleracea L. has been demonstrated in several clinical trials. Modern pharmacological studies have indicated the gastroprotective and hepatoprotective effects of P. oleracea L. by using in vivo and in vitro models. However, due to lack of information of its effects in humans, more studies should be conducted to confirm the efficacy of P. oleracea L. in humans.

Identifiants

pubmed: 30327154
pii: S0210-5705(18)30255-3
doi: 10.1016/j.gastrohep.2018.07.016
pii:
doi:

Substances chimiques

Plant Extracts 0

Types de publication

Journal Article Review

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

127-132

Informations de copyright

Copyright © 2018. Publicado por Elsevier España, S.L.U.

Auteurs

Tahereh Farkhondeh (T)

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Saeed Samarghandian (S)

Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. Electronic address: samarghandians1@nums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH